Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Sexual Arousal Disorder
Interventions: Placebo, SST-6007; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hepatic Impairment
Interventions: Tucatinib; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Tustin, California • Orlando, Florida • Knoxville, Tennessee + 1 more

Conditions: Benign Prostatic Hyperplasia
Interventions: Urocross implant, Sham-control; Device · Diagnostic Test
Lead sponsor: Prodeon Medical, Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Maywood, Illinois • Roanoke, Virginia

Conditions: Obesity, Overweight
Interventions: KAI-7535, Placebo; Drug
Lead sponsor: Kailera; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 31
States / cities: Chandler, Arizona • Phoenix, Arizona • Irvine, California + 25 more

Conditions: Insomnia
Interventions: APD125; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 173 participants
Timeline: 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Interventions: Bel-sar, Suprachoroidal Microinjector, Infrared Laser, Sham Infrared Laser, Sham Microinjector; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more

Conditions: Barth Syndrome
Interventions: Elamipretide, Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
Interventions: MMRVNS, MMRV; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Months to 6 Years
Enrollment: 1,209 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Walnut Creek, California • Miami, Florida + 12 more

Conditions: Hyperlipidemia
Interventions: Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 35
States / cities: Birmingham, Alabama • Foley, Alabama • Phoenix, Arizona + 30 more

Conditions: Pharmacokinetics
Interventions: Hutrukin, Placebo; Biological
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cytomegalovirus Infections, HIV Infections, Hypocalcemia
Interventions: Magnesium sulfate, Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: HIV
Interventions: TMC125, Placebo; Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 32
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: Irritable Bowel Syndrome (IBS), Functional Abdominal Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS), Myofacial Pain, Chronic Daily Headaches, Migraine Headaches, Chronic Pain
Interventions: Mentorship; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Years to 18 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: NODULOCYSTIC ACNE
Interventions: Finasteride 23.5 mg tablets, Finasteride 33.5 mg tablets, Placebo tablets; Drug
Lead sponsor: Elorac, Inc.; Industry
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 25
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 22 more

Conditions: Chronic Obstructive Pulmonary Disorder
Interventions: BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, FF MDI 9.6 μg, BD MDI 320 μg, Symbicort® TBH 400/12 μg BID; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 2,389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 83
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 70 more

Conditions: Healthy
Interventions: SPY002-091, Placebo; Drug · Other
Lead sponsor: Spyre Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Diabetes Mellitus Type 2
Interventions: pioglitazone, taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 57
States / cities: Buena Park, California • Chino, California • Los Angeles, California + 52 more

Conditions: Breast Cancer
Interventions: Afuresertib, Afuresertib/placebo; Drug
Lead sponsor: Laekna Limited; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more

Conditions: Extensive Stage Small Cell Lung Cancer
Interventions: [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more

Conditions: Gingival Recession
Interventions: Gintuit, autologous Free Gingival Graft (FGG); Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myocardial Infarction
Interventions: CSL112, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 1,267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Birmingham, Alabama • Huntsville, Alabama • Concord, California + 43 more

Conditions: Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions: AXS-12 (reboxetine), Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 15 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 47
States / cities: Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more

Conditions: Behcet Syndrome
Interventions: Apremilast (CC-10004), Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Jacksonville, Florida • Boston, Massachusetts • New York, New York + 1 more

Conditions: Norovirus Gastroenteritis
Interventions: VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects

Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Safety and Efficacy Study of APD125 in Patient With Insomnia

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Hutrukin to Analyze Safety and PK in Healthy Volunteers

Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents

Finasteride Treatment of Severe Nodulocystic Acne

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

A Study of SPY002-091 in Healthy Volunteers

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine